Advertisement

Drugs

, Volume 74, Issue 3, pp 377–387 | Cite as

Colistimethate Sodium Dry Powder for Inhalation: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis

  • Daniel Conole
  • Gillian M. KeatingEmail author
Adis Drug Evaluation

Abstract

Historically, the polymyxin antibacterial colistin has been administered as intravenous or nebulized colistimethate sodium in patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection. More recently, colistimethate sodium has been formulated as a dry powder (Colobreathe®) to be administered via a hand-held Turbospin® inhaler. Compared with nebulized colistimethate sodium, the colistimethate sodium dry powder for inhalation (DPI) formulation reduces treatment time and improves patient convenience. Colistimethate sodium DPI is approved in the EU for the treatment of chronic P. aeruginosa infections in patients with CF aged ≥6 years. In a phase III clinical trial in this patient population, it was determined that the change in percent predicted forced expiratory volume in 1 s with colistimethate sodium DPI 1.6625 MIU (125 mg) twice daily was noninferior to that with nebulized tobramycin 300 mg/5 mL twice daily. Moreover, patients found colistimethate sodium DPI easier to use than nebulized tobramycin. Colistimethate sodium DPI was generally well tolerated, with a similar adverse event profile to that of nebulized tobramycin, except for a numerically higher incidence of cough and abnormal taste. Most adverse events diminished after 28 days in patients receiving colistimethate sodium DPI, with an occurrence similar to that in nebulized tobramycin recipients. In conclusion, colistimethate sodium DPI administered via the Turbospin® inhaler is a useful option for the treatment of chronic P. aeruginosa infection in patients with CF aged ≥6 years.

Keywords

Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Tobramycin Colistin Polymyxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Westerman EM, Heijerman HGM, Frijlink HW. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin Drug Deliv. 2007;4(2):91–4.PubMedCrossRefGoogle Scholar
  2. 2.
    National Institute for Health and Care Excellence. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis: technology appraisal guidance. 2013. http://publications.nice.org.uk/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-ta276/clinical-need-and-practice. Accessed 19 Nov 2013.
  3. 3.
    Devesa I, Fernández-Ballester G, Ferrer-Montiel A. Targeting protein-protein interactions to rescue Δf508-cftr: a novel corrector approach to treat cystic fibrosis. EMBO Mol Med. 2013;5(10):1462–4.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microb Rev. 1996;60(3):539–74.Google Scholar
  6. 6.
    FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122(1):1–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340(1):23–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011;9:32.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Döring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16(4):749–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.PubMedCrossRefGoogle Scholar
  12. 12.
    Velkov T, Roberts KD, Nation RL, et al. Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics. Future Microbiol. 2013;8(6):711–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–69.PubMedCrossRefGoogle Scholar
  14. 14.
    European Medicines Agency. Colobreathe (colistimethate sodium): EU assessment report. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001225/WC500123693.pdf. Accessed 12 Nov 2013.
  15. 15.
    Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care. 2009;54(5):658–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8(5):295–315.PubMedCrossRefGoogle Scholar
  18. 18.
    Dodd ME, Webb AK. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med. 2000;93(Suppl 38):2–8.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Kettler LJ, Sawyer SM, Winefield HR, et al. Determinants of adherence in adults with cystic fibrosis. Thorax. 2002;57(5):459–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91–6.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Schuster A, Haliburn C, Döring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68(4):344–50.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Bergen PJ, Li J, Rayner CR, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953–8.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Li J, Turnidge J, Milne R, et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45(3):781–5.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother. 1999;43(6):1317–23.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Bergen PJ, Bulitta JB, Forrest A, et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010;54(9):3783–9.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74(3):213–23.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother. 2011;66(9):2070–4.PubMedCrossRefGoogle Scholar
  28. 28.
    MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother. 2001;48 Suppl S1:17–28.Google Scholar
  29. 29.
    Bozkurt-Guzel C, Gerceker AA. In vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa. Indian J Med Microbiol. 2012;30(1):34–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother. 2010;54(3):1117–24.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Bergen PJ, Li J, Nation RL, et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother. 2008;61(3):636–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Dudhani RV, Turnidge JD, Nation RL, et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65(9):1984–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Wang H, Wu H, Ciofu O, et al. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012;56(5):2683–90.CrossRefGoogle Scholar
  34. 34.
    Wang H, Hong W, Oana CF, et al. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2011;55(9):4469–74.CrossRefGoogle Scholar
  35. 35.
    Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros. 2012;11(4):293–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Bozkurt Güzel C, Gerçeker AA. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy. 2008;54(2):147–51.Google Scholar
  37. 37.
    Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol. 2002;34(4):257–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Tamm M, Eich C, Frei R, et al. Inhaled colistin in cystic fibrosis [in German]. Schweiz Med Wochenschr. 2000;130(39):1366–72.PubMedGoogle Scholar
  39. 39.
    Ledson MJ, Gallagher MJ, Cowperthwaite C, et al. Four years’ experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J. 1998;12(3):592–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Conway SP, Pond MN, Watson A, et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax. 1997;52(11):987–93.PubMedCrossRefGoogle Scholar
  41. 41.
    Conway SP, Etherington C, Munday J, et al. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother. 2000;34(11):1238–42.PubMedCrossRefGoogle Scholar
  42. 42.
    Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005;5:1.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Reina R, Estenssoro E, Sáenz G, et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005;31(8):1058–65.PubMedCrossRefGoogle Scholar
  44. 44.
    Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents. 2005;26(6):504–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med. 2001;7(6):434–40.PubMedCrossRefGoogle Scholar
  47. 47.
    Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857–68.PubMedCrossRefGoogle Scholar
  48. 48.
    Parisi AF, Kaplan MH. Apnea during treatment with sodium colistimethate. J Am Med Assoc. 1965;194(3):298–9.CrossRefGoogle Scholar
  49. 49.
    Falagas ME, Kasiakou SK, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res. 2006;4(2):138–46.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    European Medicines Agency. Colobreathe (colistimethate sodium): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001225/WC500123690.pdf. Accessed 6 Nov 2013.
  51. 51.
    Cunningham S, Prasad A, Collyer L, et al. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child. 2001;84(5):432–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Dodd ME, Abbott J, Maddison J, et al. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997;52(7):656–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Forest Laboratories Inc. Forest Laboratories receives European marketing approval for Colobreathe® Dry Powder Inhaler® [media release]. 2012. http://www.frx.com. Accessed 6 Jan 2014.
  54. 54.
    Forest Laboratories UK Ltd. Colomycin (colistimethate sodium) injection: UK summary of product characteristics. 2013. http://www.medicines.org.uk/emc/medicine/1590/SPC/Colomycin+Injection/. Accessed 6 Jan 2014.
  55. 55.
    Davies J, Hall P, Francis J, et al. A dry powder formulation of colistimethate sodium is safe and well-tolerated in adults and children with CF [abstract no. 278]. In: 18th Annual North American Cystic Fibrosis Conference; 6–9 Oct 2004; St Louis (MO).Google Scholar
  56. 56.
    Ratjen F, Rietschel E, Kasel D, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;57(2):306–11.PubMedCrossRefGoogle Scholar
  57. 57.
    Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care. 2011;1(1):30.PubMedCentralPubMedCrossRefGoogle Scholar
  58. 58.
    Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56(8):4241–9.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003;52(6):987–92.PubMedCrossRefGoogle Scholar
  60. 60.
    Reed MD, Stern RC, O’Riordan MA, et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001;41(6):645–54.PubMedCrossRefGoogle Scholar
  61. 61.
    Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138(6):1333–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Li J, Milne RW, Nation RL, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53(5):837–40.PubMedCrossRefGoogle Scholar
  63. 63.
    Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992;326(18):1187–91.PubMedCrossRefGoogle Scholar
  64. 64.
    Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011;10(1):54–61.PubMedCrossRefGoogle Scholar
  65. 65.
    Banerjee D, Stableforth D. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Drugs. 2000;60(5):1053–64.PubMedCrossRefGoogle Scholar
  66. 66.
    Catchpole CR, Andrews JM, Brenwald N, et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother. 1997;39(2):255–60.PubMedCrossRefGoogle Scholar
  67. 67.
    Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy. 1995;15(3):279–91.PubMedGoogle Scholar
  68. 68.
    Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25(1):11–25.PubMedCrossRefGoogle Scholar
  69. 69.
    Llor C, Bayona C, Hernández S, et al. Comparison of adherence between twice- and thrice-daily regimens of oral amoxicillin/clavulanic acid. Respirology. 2012;17(4):687–92.PubMedCrossRefGoogle Scholar
  70. 70.
    Tappenden P, Harnan S, Uttley L, et al. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model. Health Technol Assess. 2013;17(56).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations